BRAF and melanoma: In BRAF mutant melanoma and non-small cell lung cancer (NSCLC), inhibition of two components of the same oncogenic pathway (BRAF + MEK, referred to as “vertical targeting”) has been shown to provide more lasting clinical benefit compared to inhibition of only BRAF4,5.